Base de dados : HANSEN
Pesquisa : CLOFAZIMINA/ADMIN [Descritor de assunto]
Referências encontradas : 25 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 25 HANSEN  
              next record last record
seleciona
para imprimir
Texto Completo-en
Id:27119
Autor:Katoch, Kiran; Ramu, Gopal; Ramanathan, Usha; Sengupta, Utpal; Sharma, Vishnu D; Shivannavar, Channappa T; Katoch, Vishwa M.
Título:Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Fonte:Int J Lepr;57(2):451-457, June 1989. ^bgraf, ^btab.
Resumo: regimen consisting of 600 mg of rifampin once a month, 100 mg of clofazimine on alternate days, and 100 mg of dapsone daily was used in 56 untreated, highly bacillated borderline lepromatous/lepromatous (BL/LL) patients with an average bacterial index (BI) of 4.45. Treatment was continued until skin-smear negativity. After 2 years of therapy, none of the patients had become smear negative and the average BI was 2.56. There was no growth on inoculation of skin-tissue biopsies in the normal mouse foot pad after 6 months of therapy. Bacillemia was still detectable in 11/50 patients, and significant ATP levels were detected in Mycobacterium leprae from skin-tissue biopsies in 16% of the cases. After 3 years of therapy, three patients had become smear negative. The average BI was 1.30. None of the patients had detectable bacillemia, and 5% of the cases showed detectable ATP levels in M. leprae from tissue biopsies. After 4 years of therapy, 41.7% of the patients had become smear negative. The average BI was 0.66, and no ATP was detected in any of the purified bacillary suspensions. The fall in BI was accelerated, and more patients on continued treatment became negative earlier compared to those having treatment for a limited duration, as reported by others^ien.
Descritores:Clofazimina/admin
Clofazimina/uso terap
Dapsona/admin
Dapsona/uso terap
Hanseníase Dimorfa/microbiol
Hanseníase Virchowiana/microbiol
Limites:Humanos
Adolescente
Adulto
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a01.pdf - en.
Localização:Br191.1


  2 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:25129
Autor:Leonard Wood Memorial*.
Título:A statistical analysis of two chemotherapy trials in lepromatous leprosy: II. Interactions among patient variables
..-
Fonte:s.l; s.n; 1978. 4 p. tab.
Resumo:Interrelationship among six patient characteristics recorded upon entry the trial were analyzed for 67 patients with lepromatous and near-lepromatous leproay admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of older patients and of patients classified as borderline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological grounds were classified fully lepromatous by the clinical criteria. Measurments of the number of Mycobacterium leprae in the patients made by there methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the hand, and any of the measurments of the numbers of organisms on the other (AU).
Descritores:HANSENIASE DIMORFA/terap
HANSENIASE VIRCHOWIANA/terap
CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
DAPSONA/uso terap
HANSENIASE DIMORFA/microbiol
HANSENIASE DIMORFA/patol
HANSENIASE VIRCHOWIANA/microbiol
HANSENIASE VIRCHOWIANA/patol
QUIMIOTERAPIA COMBINADA
 DROGAS EM INVESTIGACAO/admin
 DROGAS EM INVESTIGACAO/uso terap
Limites:ESTUDO COMPARATIVO
HUMANO
Localização:BR191.1; 00294/s


  3 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18995
Autor:Salafia, A; Ghauhan, G.
Título:Clofazimine crystals and ceroid bodies in nerve: a case report.
Fonte:Fontilles - Revista de Leprología;19(1):73-76, Ene.-Abr. 1993. .
Resumo:Clofazimina in one of the most widely used in leprosy bacause of its anti-bacteriostatic and anti-inflammatory activit deposition of clofaznine has been reported in various organs and body tissues, however, the authors think the deposition of clofazinime crystals in nerve tissue, as fas as we know has never been reported. (AU).
Descritores:CLOFAZIMINA
CEROIDE
CLOFAZIMINA/admin
Limites:RELATO DE CASO
Localização:BR191.1


  4 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18952
Autor:Murray, Clinton K; Joyce, M. Patricia; Longfield, Robert N
Título:Short report: treatment failure in Hanse´n's disease
..-
Fonte:s.l; s.n; 2003. 2 p. tab.
Resumo:Areas of low endemicity of Hansen's disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections. Managing this disease in these areas of low endemicity is difficult, especially in observing for relapse. The accurate diagnosis of relapse is imperative so that appropriate therapy can be promptly reinstituted and unnecessary treatment can be avoided. To assess treatment failures in an area of low endemicity, we retrospectively evaluated 113 patients with Hansen's disease treated in southern Texas. Of 57 patients who completed therapy, 11 were later restarted on medications for this disease for presumed relapse. However, nine of the 11 were found not to have true relapses of Hansen's disease. The accurate diagnosis of relapse of this disease is essential not only in the individual patient but also for prospective treatment trials to establish best practices. (AU).
Descritores:CLOFAZIMINA/admin
DAPSONA/admin
QUIMIOTERAPIA COMBINADA
HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENIASE/patol
HANSENIASE/prev
REGISTROS MEDICOS
RECIDIVA
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
TEXAS/epidemiol
FALHA DE TRATAMENTO
RECUSA DO PACIENTE AO TRATAMENTO
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 09084/s


  5 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18489
Autor:Goulart, Isabela Maria Bernades; Arbex, Guilherme Leonel; Carneiro, Marcus Hubaide; Rodrigues, Mariana Scalia; Gadia, Rafael
Título:Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia
Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia-
Fonte:s.l; s.n; set.-out. 2002. 8 p. tab.
Resumo:The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem. (AU).
Descritores:CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
DAPSONA/admin
DAPSONA/ef adv
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENIASE/quimioter
COOPERACAO DO PACIENTE/estatíst
DESISTÊNCIA DO PACIENTE/estatíst
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
RIFAMPINA/ef adv
Limites:PRÉ-ESCOLAR
CRIANÇA
ADOLESCENCIA
ADULTO
RESUMO EM INGLES
FEMININO
HUMANO
LACTENTE
RECEM-NASCIDO
MASCULINO
MEIA-IDADE
Localização:BR191.1; 09017/s


  6 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18476
Autor:Queiroz, Regina Helena Costa; Souza, Ana Maria de; Sampaio, Suely Vilela; Melchior Junior, Enzo
Título:Biochemical and hematological side effects of clofazimine in leprosy patients
..-
Fonte:s.l; s.n; 2002. 4 p. tab.
Resumo:Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients. (AU).
Descritores:CONTAGEM DE CELULAS SANGUINEAS
CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/ef adv
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/uso terap
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/ef adv
RIFAMPINA/uso terap
Limites:SUPPORT, NON-U.S. GOV'T
FEMININO
HUMANO
MASCULINO
Meio Eletrônico: - .
Localização:BR191.1; 08998/s


  7 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18448
Autor:Waters, M. F. R
Título:New approaches to chemotherapy for leprosy
..-
Fonte:s.l; s.n; dec. 1983. 3 p. .
Resumo:The treatment of leprosy with sulfones was introduced in 1943 and, perhaps surprisingly, drug resistance was not detected for many years. Proven dapsone resistance was first reported in 1964 by Pettit and Rees from the Sungei Buloh Leprosarium, Malaysia.(AU).
Descritores:QUIMIOTERAPIA COMBINADA
DAPSONA/admin
RIFAMPINA/admin
CLOFAZIMINA/admin
HANSENOSTATICOS/admin
HANSENIASE/quimioter
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 01651/s


  8 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18334
Autor:Waters, M. F. R
Título:New approaches to chemotherapy for leprosy
..-
Fonte:s.l; s.n; 1983. 3 p. .
Resumo:The treatment of leprosy with sulphones was introduced in 1943 and, perhaps surprisingly, drug resistance was not detected for many years. Proven dapsone resistance was first reported in 1964 by Pettit and Rees from the Sungei Buloh Lperosarium, Malaysia. (AU).
Descritores:HANSENIASE/quimioter
RIFAMPINA/admin
QUIMIOTERAPIA COMBINADA
CLOFAZIMINA/admin
HANSENOSTATICOS/admin
DAPSONA/admin
Limites:HUMANO
Localização:BR191.1; 04896/s


  9 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18295
Autor:Abdul Razack, E. M; Zahra, A
Título:Multi-drug treatment for reactions in leprosy
..-
Fonte:s.l; s.n; apr. 1981. 9 p. tab.
Resumo:Thirty three leprosy patients in reaction were treated with a combination of Metronidazole-Dehyl carbamazine citrate - Chloroquin which was reinforced either with prednisolone and or Clofazimine in some, depending on the clinical state. The results were quite encouraging as to encountering leprosy patients i recation early during the maiden spell - at no time in any case was dapsone with drawn.(AU).
Descritores:CLOROQUINA/admin
CLOFAZIMINA/admin
DIETILCARBAMAZINA/admin
QUIMIOTERAPIA COMBINADA
HANSENIASE/compl
HANSENIASE/quimioter
METRONIDAZOL/admin
PREDNISOLONA/admin
Limites:CRIANÇA
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 00693/s


  10 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17947
Autor:Ramu, G; Sreevatsa; Sengupta, U; Desikan, K. V
Título:Evaluation of multiple regimens in leprosy
..-
Fonte:s.l; s.n; apr. 1981. 7 p. tab, graf.
Resumo:Assessment of bacteraemia has been made at weekly intervals in 36 lepromatous leprosy patients who were put on different antileprosy drug under four regimens, viz., DDS alone, DDS in combination with rifampicin (DDS + RIF), clofazimine (DDS + CLF) and thiacetazone (DDS + TCT). In general, with the continuation of treatment the bacillary load in the blood decreased considerably while bacteriological index (BI) of the skin remained constant during the study. No significant difference was noted in M. leprae clearance from blood between the groups treated with DDS alone and groups treated in combination with CLF and TCT. However, DDS + RIF treatment was most efficient in clearing acid-fast bacilli (AFB) from blood as compared to those noted with other drug regimens.(AU).
Descritores:HANSENIASE/quimioter
RIFAMPINA/admin
SEPTICEMIA/quimioter
QUIMIOTERAPIA COMBINADA
DAPSONA/ef adv
TIOACETAZONA/admin
CLOFAZIMINA/admin
AVALIACAO DE MEDICAMENTOS
Limites:ESTUDO COMPARATIVO
HUMANO
MASCULINO
Meio Eletrônico: - .
Localização:BR191.1; 00696/s


  11 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17839
Autor:Bourée, P; Carré, N; Drahmane, S
Título:Guinée: dépistage de la lèpre et traitement par polychimiothérapie
Guinea: detection of leprosy and treatment by polychemotherapy-
Fonte:s.l; s.n; 1988. 9 p. mapas, tab.
Resumo:Since a year, the implementation of multidrug therapy on leprosy control in Guinea has been needing a good cooperation between Department of Leprosy Control and local nurses. The known prevalence, in the area of Pita is 1.23%. 246 patients has been detected: 36 multibacillary and 210 paucibacillary. The sex-ratio of the patients has changed, during one year, toward the men. With the sensitivity of the local population, number of detected cases is increasing and the rate of regular attendance at treatment is correct in 87.6% of cases.(AU).
Descritores:HANSENIASE/quimioter
HANSENIASE/epidemiol
RIFAMPINA/admin
RIFAMPINA/uso terap
AFRICA OCIDENTAL
CLOFAZIMINA/admin
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
Limites:HUMANO
MASCULINO
FEMININO
RESUMO EM INGLES
Meio Eletrônico: - .
Localização:BR191.1; 02055/s


  12 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17835
Autor:Pieters, F. A; Woonink, F; Zuidema, J
Título:Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria
..-
Fonte:s.l; s.n; 1988. 4 p. tab, graf.
Resumo:In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.(AU).
Descritores:CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/farmacol
DAPSONA/admin
DAPSONA/sangue
DAPSONA/farmacocin
DAPSONA/uso terap
Limites:HUMANO
MASCULINO
FEMININO
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 02067/s


  13 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16347
Autor:Bourée, P; Brette, A. de; Carsalade, G. Y. de
Título:Réaction lépreuse tardive apparue 18 mois après la fin d'un traitement
Late reversal leprous reaction appearing 18 months after the termination of treatment-
Fonte:s.l; s.n; mars 2001. 1 p. .
Descritores:ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
BIOPSIA
CLOFAZIMINA
CLOFAZIMINA
TINTURAS
SEGUIMENTOS
HIPERSENSIBILIDADE TARDIA
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
PREDNISONA
PREDNISONA
PELE
FATORES DE TEMPO
Limites:RELATO DE CASO
Localização:BR191.1; 08684/s


  14 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15972
Autor:Flageul, B; Wagner, L; Cottenot, F
Título:Accidents immuno-allergiques à la rifampicine
..-
Fonte:s.l; s.n; 2002. 8 p. tab.
Descritores:HANSENIASE
HANSENIASE DIMORFA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
RIFAMPINA
RIFAMPINA
RIFAMPINA
RIFAMPINA
SULFONAMIDAS
SULFONAMIDAS
TROMBOCITOPENIA
TROMBOCITOPENIA
ANTIBIOTICOS COMBINADOS
CLOFAZIMINA
CLOFAZIMINA
DAPSONA
DAPSONA
HIPERSENSIBILIDADE A DROGAS
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
Localização:BR191.1; 08568/s


  15 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15466
Autor:Bourée, P; Brette, A. de; Carsalade, G. Y. de
Título:Réaction lépreuse tardive apparue 18 mois après la fin d'un traitement
Late reveral leprous reaction appearing 18 months after the termination of treatment-
Fonte:s.l; s.n; 2001. 1 p. .
Descritores:ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
BIOPSIA
CLOFAZIMINA
CLOFAZIMINA
TINTURAS
SEGUIMENTOS
HIPERSENSIBILIDADE TARDIA
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
PREDNISONA
PREDNISONA
PELE
FATORES DE TEMPO
Limites:RELATO DE CASO
Localização:BR191.1; 08321/s


  16 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15323
Autor:Welsh, Oliverio; Gomes, Minerva; Mancias, Cecilia; Ibarra-Leal, Sara; Millikan, Larry E
Título:A new therapeutic approach to type II leprosy reaction
..-
Fonte:s.l; s.n; 1999. 3 p. ilus.
Descritores:CLOFAZIMINA
QUIMIOTERAPIA COMBINADA
ERITEMA NODOSO
ERITEMA NODOSO
LEPROSTATICOS
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
PENTOXIFILINA
Localização:BR191.1; 07244/s


  17 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14197
Autor:Queiroz, Regina Helena Costa; Melchior Junior, Enzo; Souza, Ana Maria de; Gouveia, Elias; Barbosa, Jose Carlos; Carvalho, Dermeval de
Título:Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT
..-
Fonte:s.l; s.n; 1997. 5 p. tab.
Descritores:HANSENIASE
HANSENIASE
CLOFAZIMINA
CLOFAZIMINA
DAPSONA
DAPSONA
QUIMIOTERAPIA COMBINADA
LEPROSTATICOS
METEMOGLOBINEMIA
RIFAMPINA
RIFAMPINA
Localização:BR191.1; 07131/s


  18 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14135
Autor:Moubasher, Alaa El-Din A; Kamel, Neveen A; Zedan, Hatem; Raheem, Diaa El-Din Abdel
Título:Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy
..-
Fonte:s.l; s.n; 1998. 6 p. tab, graf.
Descritores:HANSENIASE
HANSENIASE
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
LEPROSTATICOS
LEPROSTATICOS
CORTICOSTEROIDES
CORTICOSTEROIDES
CLOFAZIMINA
CLOFAZIMINA
CITOCINAS
CITOCINAS
INTERLEUCINA-1
INTERLEUCINA-10
RECEPTORES DA INTERLEUCINA 2
RECEPTORES DA INTERLEUCINA 2
Localização:BR191.1; 07110/s


  19 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14110
Autor:Anon
Título:Leprosy
..-
Fonte:s.l; s.n; 1997. 1 p. .
Descritores:CLOFAZIMINA
DAPSONA
QUIMIOTERAPIA COMBINADA
LEPROSTATICOS
HANSENIASE
RIFAMPINA
Localização:BR191.1; 07052/s


  20 / 25 HANSEN  
              first record previous record
seleciona
para imprimir
Id:13966
Autor:Sehgal, Virendra N; Bhattacharya, Sambit N; Chattopadhaya, Debasish; Saha, Kunal
Título:Tumor necrosis factor: status in reactions in leprosy before and after treatment
..-
Fonte:s.l; s.n; 1993. 4 p. tab, graf.
Descritores:ADMINISTRAÇAO ORAL
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
CLOROQUINA
CLOROQUINA
CLOROQUINA
CLOFAZIMINA
CLOFAZIMINA
ERITEMA NODOSO
ERITEMA NODOSO
HIPERSENSIBILIDADE TARDIA
HIPERSENSIBILIDADE TARDIA
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
PREDNISOLONA
PREDNISOLONA
COMPRIMIDOS
FATOR DE NECROSE DE TUMOR
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
Localização:BR191.1; 06612/s



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information